Mani Foroohar
Stock Analyst at Leerink Partners
(1.47)
# 3,157
Out of 4,765 analysts
182
Total ratings
41.18%
Success rate
-14.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $6.17 | -2.76% | 8 | Feb 28, 2025 | |
FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.24 | +536.79% | 9 | Jan 13, 2025 | |
RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $8.70 | +406.04% | 10 | Nov 19, 2024 | |
LXEO Lexeo Therapeutics | Maintains: Outperform | $20 → $19 | $2.91 | +552.92% | 2 | Nov 13, 2024 | |
NGNE Neurogene | Maintains: Outperform | $45 → $72 | $17.78 | +304.95% | 2 | Nov 12, 2024 | |
CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $5.28 | +221.97% | 1 | Nov 5, 2024 | |
MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $45.03 | +8.82% | 11 | Oct 17, 2024 | |
BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $32.59 | +41.15% | 15 | Oct 17, 2024 | |
WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $10.81 | +103.52% | 6 | Oct 16, 2024 | |
IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $33.41 | +85.57% | 15 | Jul 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $14.49 | -10.28% | 1 | Jul 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $22.77 | +27.36% | 1 | Jul 2, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $99.65 | +130.81% | 1 | Jun 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $3.16 | +26.58% | 2 | Apr 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $6.65 | - | 10 | Mar 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $5.29 | +486.01% | 1 | Feb 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $23 | $9.67 | +137.85% | 10 | Dec 22, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.62 | +1,028.12% | 1 | Nov 30, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $15.77 | +153.65% | 12 | May 12, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $36.43 | +155.32% | 17 | Feb 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.62 | +773.18% | 4 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.50 | +366.67% | 4 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $3.82 | +4,088.48% | 10 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $27.48 | +180.20% | 2 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $240.96 | -40.65% | 11 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.59 | +7.33% | 5 | Nov 14, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $43.47 | +74.83% | 1 | Nov 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.05 | +3,138.10% | 4 | May 12, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.83 | +314.08% | 6 | Jul 23, 2021 |
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $6.17
Upside: -2.76%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.24
Upside: +536.79%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $8.70
Upside: +406.04%
Lexeo Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $20 → $19
Current: $2.91
Upside: +552.92%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.78
Upside: +304.95%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $5.28
Upside: +221.97%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $45.03
Upside: +8.82%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $32.59
Upside: +41.15%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $10.81
Upside: +103.52%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $33.41
Upside: +85.57%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $14.49
Upside: -10.28%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $22.77
Upside: +27.36%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $99.65
Upside: +130.81%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.16
Upside: +26.58%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $6.65
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $5.29
Upside: +486.01%
Dec 22, 2023
Downgrades: Market Perform
Price Target: $23
Current: $9.67
Upside: +137.85%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.62
Upside: +1,028.12%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $15.77
Upside: +153.65%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $36.43
Upside: +155.32%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.62
Upside: +773.18%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.50
Upside: +366.67%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $3.82
Upside: +4,088.48%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $27.48
Upside: +180.20%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $240.96
Upside: -40.65%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.59
Upside: +7.33%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $43.47
Upside: +74.83%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.05
Upside: +3,138.10%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.83
Upside: +314.08%